OCUP - Ocuphire Pharma, Inc.

QQQ $ 454.82 $ 3.15 (0.7 %)

DIA $ 398.57 $ -1.85 (-0.46 %)

SPY $ 530.36 $ 0.61 (0.12 %)

TLT $ 91.26 $ -0.27 (-0.3 %)

GLD $ 225.37 $ 0.90 (0.4 %)

Previous Close

$ 1.79

Open

$ 1.78

Bid

$ 1.77 x 400

Ask

$ 1.79 x 400

Day's Range

$ 1.71 - $ 1.85

52 Week Range

$ 1.50 - $ 4.58

Volume

227,482

Average Volume

Market Cap

43.89M

Beta (5Y Monthly)

$ 1.01

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-10-2024	03-31-2024	10-Q
2	03-08-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-11-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-30-2023	12-31-2022	10-K
7	11-04-2022	09-30-2022	10-Q
8	08-12-2022	06-30-2022	10-Q
9	05-13-2022	03-31-2022	10-Q
10	03-24-2022	12-31-2021	10-K
11	11-12-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-07-2021	03-31-2021	10-Q
14	03-11-2021	12-31-2020	10-K
15	10-29-2020	09-30-2020	10-Q
16	08-14-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	02-21-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-10-2019	03-31-2019	10-Q
22	03-07-2019	12-31-2018	10-K
23	11-02-2018	09-30-2018	10-Q
24	08-03-2018	06-30-2018	10-Q
25	05-04-2018	03-31-2018	10-Q
26	03-09-2018	12-31-2017	10-K
27	11-03-2017	09-30-2017	10-Q
28	08-04-2017	06-30-2017	10-Q
29	05-03-2017	03-31-2017	10-Q
30	02-24-2017	12-31-2016	10-K
31	11-04-2016	09-30-2016	10-Q
32	08-05-2016	06-30-2016	10-Q
33	05-06-2016	03-31-2016	10-Q
34	03-14-2016	12-31-2015	10-K
35	11-02-2015	09-30-2015	10-Q
36	08-07-2015	06-30-2015	10-Q
37	05-08-2015	03-31-2015	10-Q
38	03-16-2015	12-31-2014	10-K
39	11-12-2014	09-30-2014	10-Q
40	08-13-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Canaccord Genuity Maintains Buy on Ocuphir...
05/13/2024 16:40:53

Canaccord Genuity analyst John Newman maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $2...

HC Wainwright & Co. Reiterates Buy on Ocup...
05/13/2024 10:46:55

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...

Ocuphire Pharma Q1 2024 GAAP EPS $(0.29) M...
05/10/2024 12:07:55

Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0...

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
04/11/2024 20:31:16

$ocuphire-pharma-announces-first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-ophthalmic-solution-075-ps-for-the-treatment-of-decreased-visual-acuity-under-low-light-conditions-following-keratorefractive-surgery$

Ocuphire Pharma Announces First Patient En...
04/11/2024 14:05:39

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., Apr...

Ocuphire Announces the US Commercial Launc...
04/01/2024 11:17:13

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...

design-therapeutics-and-2-other-stocks-under-5-insiders-are-buying

Design Therapeutics And 2 Other Stocks Und...
03/26/2024 11:37:52

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confid...

Alliance Global Partners Maintains Buy on ...
03/20/2024 12:10:43

Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target...

HC Wainwright & Co. Reiterates Buy on Ocup...
03/11/2024 11:36:35

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...

Ocuphire Pharma Q4 2023 GAAP EPS $(0.210) ...
03/08/2024 13:05:38

Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.210) per share which missed the analyst consensus estimate of $(...

Ocuphire Pharma Strengthens Leadership Tea...
02/14/2024 13:17:48

Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief...

Ocuphire Pharma Announces Presentation On ...
02/05/2024 13:05:56

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...

Ocuphire Pharma Receives FDA Agreement Und...
01/04/2024 13:02:13

Ocuphire Pharma Announces Appointment Of J...
11/27/2023 13:10:06

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...

A Look Into Healthcare Sector Value Stocks
11/20/2023 14:44:32

HC Wainwright & Co. Reiterates Buy on Ocup...
11/14/2023 12:13:13

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...

Recap: Ocuphire Pharma Q3 Earnings
11/13/2023 14:10:11

Ocuphire Pharma Q3 EPS $0.25 Vs $(0.22) Yo...
11/13/2023 13:03:38

overview-of-value-stocks-in-the-healthcare-sector

Overview Of Value Stocks In The Healthcare...
11/06/2023 14:44:08

Ocuphire Pharma Announces Successful End-o...
11/02/2023 12:10:11